Phase 1 clinical trials of a selective rho kinase inhibitor, k-115

JAMA Ophthalmology

Volumn 131, Issue 10, 2013, Pages 1288-1295

  Tanihara, Hidenobu ^a   Inoue, Toshihiro ^a   Yamamoto, Tetsuya ^b   Kuwayama, Yasuaki ^c   Abe, Haruki ^d   Araie, Makoto ^e  

^a KUMAMOTO UNIVERSITY   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Fukushima Eye Clinic   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

^e Public School Teachers   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

K 115; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; COMPARATIVE STUDY; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE EXAMINATION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, TOPICAL; ADULT; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; HUMANS; INTRAOCULAR PRESSURE; ISOQUINOLINES; MALE; OPHTHALMIC SOLUTIONS; RHO-ASSOCIATED KINASES; SULFONAMIDES; TONOMETRY, OCULAR; VISUAL ACUITY; YOUNG ADULT;

EID: 84885929097     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.323     Document Type: Article

References (34)

1. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325(20):1412-1417.
2. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440.
3. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279. (Pubitemid 36105431)
4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713; 829-830.
5. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49(3):389-402. (Pubitemid 19239397)
6. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol. 1978;96(11):2045-2048. (Pubitemid 8404089)
7. Lippa EA, Carlson LE, Ehinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992;110(4):495-499.
8. Gaasterland D, Kupfer C, Ross K. Studies of aqueous humor dynamics in man, IV: effects of pilocarpine upon measurements in young normal volunteers. Invest Ophthalmol. 1975;14(11): 848-853.
9. Tian B, Gabelt BT, Geiger B, Kaufman PL. The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res. 2009;88(4):713-717.
10. Tian B, Kaufman PL, Volberg T, Gabelt BT, Geiger B. H-7 disrupts the actin cytoskeleton and increases outflow facility. Arch Ophthalmol. 1998;116(5):633-643. (Pubitemid 28414579)
11. Epstein DL, Rowlette LL, Roberts BC. Acto-myosin drug effects and aqueous outflow function. Invest Ophthalmol Vis Sci. 1999;40(1):74-81. (Pubitemid 29029574)
12. Honjo M, Tanihara H, Inatani M, et al. Effects of Rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42(1):137-144. (Pubitemid 32059420)
13. Koga T, Koga T, Awai M, Tsutsui J, Yue BY, Tanihara H. Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells. Exp Eye Res. 2006;82(3):362-370. (Pubitemid 43138949)
14. Kameda T, Inoue T, Inatani M, et al. The effect of Rho-associated protein kinase inhibitor on monkey Schlemm's canal endothelial cells. Invest Ophthalmol Vis Sci. 2012;53(6):3092-3103.
15. Honjo M, Inatani M, Kido N, et al. A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes. Exp Eye Res. 2002;75(2):135-142.
16. Honjo M, Inatani M, Kido N, et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol. 2001;119(8):1171-1178. (Pubitemid 32730005)
17. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126(3): 309-315. (Pubitemid 351398453)
18. Williams RD, Novack GD, van Haarlem T, Kopczynski C; AR-12286 Phase 2A Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011;152(5):834-841.e1.
19. Mizuno K, Koide T, Fujieda Y, et al. Ocular hypotensive and neuroprotective effects of K-115, a novel Rho-kinase inhibitor [ARVO E-Abstract 4805]. Invest Ophthalmol Vis Sci. 2007:48.
20. Mizuno K, Ohta M, Mori J, et al. Effects of K-115, a Rho-kinase inhibitor, on aqueous humor dynamics in rabbits [ARVO E-Abstract 1640]. Invest Ophthalmol Vis Sci. 2008:49.
21. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42(5):1029-1037. (Pubitemid 32289800)
22. Rao PV, Deng P, Sasaki Y, Epstein DL. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp Eye Res. 2005;80(2):197-206.
23. Okka M, Tian B, Kaufman PL. Effect of low-dose latrunculin B on anterior segment physiologic features in the monkey eye. Arch Ophthalmol. 2004;122(10):1482-1488. (Pubitemid 39336548)
24. Grosheva I, Vittitow JL, Goichberg P, et al. Caldesmon effects on the actin cytoskeleton and cell adhesion in cultured HTM cells. Exp Eye Res. 2006;82(6):945-958. (Pubitemid 44287907)
25. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389(6654):990-994. (Pubitemid 27485693)
26. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem. 1996;120(2):215-228. (Pubitemid 26335910)
27. Koseki N, Araie M, Tomidokoro A, et al. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology. 2008;115(11):2049-2057.
28. Hitchings RA. Therapeutic rationale for normal-tension glaucoma. Curr Opin Ophthalmol. 1995;6(2):67-70.
29. Watabe H, Abe S, Yoshitomi T. Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries. Jpn J Ophthalmol. 2011;55(4):411-417.
30. Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of Y-39983, a selective Rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48(7):3216-3222. (Pubitemid 351261166)
31. Tokushige H, Waki M, Takayama Y, Tanihara H. Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr Eye Res. 2011;36(10):964-970.
32. Yoshioka T, Nakabayashi S, Nagaoka T, Tani T, Yoshida A. Effect of intravitreal Rho kinase inhibitors on retinal microcirculation in cats [ARVO E-Abstract 6855]. Invest Ophthalmol Vis Sci. 2012:53.
33. Hirata A, Inatani M, Inomata Y, et al. Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia. Graefes Arch Clin Exp Ophthalmol. 2008;246(1):51-59. (Pubitemid 350162684)
34. Sagawa H, Terasaki H, Nakamura M, et al. A novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats. Exp Neurol. 2007;205(1):230-240. (Pubitemid 46617509)